Chris Schade

Chris Schade is a seasoned executive with over 30 years of experience across private and public biopharma companies, including proven leadership in several executive roles. He currently serves as President and Chief Executive Officer of Halda Therapeutics. Prior to Halda, Mr. Schade was a Growth Partner at Flagship Pioneering. Previously, Mr. Schade was President and Chief Executive Office of Aprea Therapeutics, where he has been serving as a member of the board since 2016 and as Chairman of the board since 2020. Prior to Aprea, he held leadership positions at Novira, Omthera Pharmaceuticals and Medarex. In addition to industry expertise, Mr. Schade brings extensive corporate finance and capital markets experience from the investment banking industry, with roles at Merrill Lynch and JP Morgan Chase & Co. In addition to Aprea Therapeutics, Mr. Schade also serves on the board of directors of Sapience Therapeutics, Inc., Integra LifeSciences Inc., Ring Therapeutics and Alltrna Therapeutics.

Mr. Schade received a Master of Business Administration from the Wharton School at the University of Pennsylvania and a Bachelor of Arts from Princeton University.